Science

Articles

• How blood–brain barrier technology is unleashing CNS therapies
  18 March, by Emmanuelle BETTENDORF

  We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.
  This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.
  Click below for the full article.
  👉 (…)

• Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme
  8 July 2021, by Elodie DORMES

  Vect-Horus and RadioMedix are pleased to announce the FDA clearance of eIND application to evaluate 68Ga-RMX-VH for the diagnostic of GBM.

• mRNA Based Therapeutics poster
  3 February, by Emmanuelle BETTENDORF

  Pavlo Shpak-Kraievskyi is presenting a poster on behalf of Vect-Horus at the 4th Annual mRNA-Based Therapeutics Summit Europe, taking place January 28-30 in Frankfurt, Germany.
  Effective delivery of mRNA therapeutics to the central nervous system (CNS) remains a significant challenge due to the protective blood-brain barrier (BBB). The poster, entitled “VECTrans® Technology for CNS Targeting with Lipid Nanoparticles”, outlines results from a study of VECTrans® enabling the targeted (…)

• Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
  14 November 2024, by Emmanuelle BETTENDORF

  We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
  Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
  “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)

• Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
  22 April 2024, by Emmanuelle BETTENDORF

  Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
  The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides (…)

• Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
  15 May 2024, by Emmanuelle BETTENDORF

  The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
  The study showed that these vectors have the potential to improve delivery of medication to the (…)

• RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
  15 November 2022, by Elodie DORMES

  Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) — RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC). This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers. 68Ga-RMX-VH is a (…)

• Vect-Horus will join the Single-Domain Antibodies Summit
  14 September 2023, by Emmanuelle BETTENDORF

  Vect-Horus Vector Discovery Team will attend the Single Domain Antibodies Summit that will be held in Paris from 18th to 20th of September 2023.
  Interesting sessions are planned and Vect-Horus will attend the one dedicated to “Single domain Antibodies engineering and structure” and of course “Single domain Antibodies in neurobiology”.
  We look forward to discussing with the scientific community attending this meeting and sharing with them our last advances in the use of nanobodies as (…)

• Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023
  12 October 2023, by Emmanuelle BETTENDORF

  Vect-Horus team will attend the 19th Annual Meeting of the Oligonucleotide Therapeutics Society from October 22nd to 25th, 2023, in Barcelona.
  We are pleased to announce that Guillaume Jacquot, Program Director, Brain & Tissue Targeting of Oligonucleotides, will give a talk entitled “TfR-targeted functional delivery of oligonucleotides to CNS tissues by local and systemic administration” on Tuesday, 24th and Emmanuelle Bettendorf, Senior Business Developer, will also be there and (…)

• Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!
  8 September 2023, by Emmanuelle BETTENDORF

  On this occasion, our partner Radiomedix, Inc. , was selected to present an update of our joint research program. This talk untitled “Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein Receptors (LDLR)” will be given Sunday, September 10th between 4:55 PM and 5:05 PM at the Hall E2 by Izabela Tworowska.
  Come and take the opportunity to meet and discuss with Vect-Horus on September 9-13, 2023 in Vienna!
  Our #Oncology team, Cedric (…)